CardioExchange Archive

November 21st, 2014

Encouraging Results For Two New Drugs For Hyperkalemia

Larry Husten, PHD

Two new agents under development may help curb and prevent hyperkalemia, the common and serious side effect of drugs that inhibit the renin-angiotensin-aldosterone system (RAAS), which are the cornerstones of the treatment of chronic kidney disease and heart failure. … Click here to read the full post on Forbes.  

---

November 3rd, 2014

A “Big Data” Approach to Phenotype-Based Clustering of Heart Failure Patients

Tariq Ahmad, MD, MPH

Tariq Ahmad discusses his research group’s study of clinical phenotypes in patients with chronic systolic heart failure.

---

October 13th, 2014

Heart Failure Readmissions: Neighborhood Factors Matter, Too

Behnood Bikdeli, M.D.

For two decades, investigators have been studying the association between neighborhood characteristics and cardiovascular disease. A landmark study from 2001 showed that living in a socioeconomically disadvantaged neighborhood was associated with higher incidence of coronary artery disease. Several studies have also shown an association between neighborhood characteristics, most notably the socioeconomic status (SES) and outcomes […]

---

September 29th, 2014

The Implications of PARADIGM-HF for Clinical Practice

Clyde Yancy, MD and Mary Norine Walsh, MD

Clyde Yancy and Mary Norine Walsh offer their perspectives on the much-discussed PARADIGM-HF trial.

---

September 15th, 2014

New Observations on Saxagliptin

Benjamin Scirica, MD MPH

Benjamin Scirica discusses his study group’s new analysis of data from the SAVOR-TIMI 53 randomized, placebo-controlled trial of saxagliptin in patients with type 2 diabetes.

---

September 11th, 2014

Race and Ethnicity Do Not Affect the Benefits of Device Therapy in Heart Failure

Boback Ziaeian, MD

Boback Ziaeian discusses his observational study exploring the benefits of guideline-recommended cardiac resynchronization therapy and ICD therapy in heart failure patients, according to race and ethnicity.

---

September 5th, 2014

Perspectives on PARADIGM-HF

CardioExchange Editors, Staff

The Editors present a distillation of reader comments on a popular post.

---

September 1st, 2014

Let’s Take a Close Look at PARADIGM-HF

Vinay Prasad, MD MPH

Vinay Prasad explores three reasons why clinicians should have reservations about the findings from PARADIGM-HF.

---

August 31st, 2014

SIGNIFY Trial Provokes Sound and Fury Over Controversial Drug

Larry Husten, PHD

The already controversial drug ivabradine just got a little more controversial. The drug, which is marketed by Servier under the brand names of Corlentor and Procoralan, is available in Europe and elsewhere and is used for the treatment of heart failure and stable angina. The drug is not available in the U.S., but it is under development by Amgen for a […]

---

August 30th, 2014

Will There Be a PARADIGM Shift in Treatment of Heart Failure?

John McMurray, MbChB MD and Milton Packer, MD

John J.V. McMurray and Milton Packer, the two lead authors of the PARADIGM-HF trial, discuss the randomized comparison of angiotensin–neprilysin inhibition with the ACE inhibitor enalapril.

---